Curated news and analysis on clinical trials, drug approvals, and medical research.
Nature Communications findings showed NR2F6 deletion revived exhausted CAR-T cells and boosted activity against solid tumors. In murine models, modified cells drove tumor regression, prolonged survival and resistance to rechallenge.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
Adial Pharmaceuticals completed demonstration batch production for AD04, meeting prespecified specifications and matching the prior Phase 2 dissolution profile. The step enables clinical and registration batch production for the planned Phase 3 trial.
The Veterinary Medicines Directorate will launch a new digital service for reporting animal medicine adverse events on 20 May 2026. The beta service will replace the previous suspended tool and integrate with existing pharmacovigilance processes.
AsedaSciences signed a commercial agreement with Clyde Biosciences to integrate the CellOPTIQ cardiotoxicity screen into its 3RnD platform. The deal adds a validated in vitro CiPA assay for chemical and drug safety assessment.
A study in Cell suggests a urine DNA test may help identify which people with non-muscle invasive bladder cancer are likely to benefit from BCG immunotherapy. The test detected minimal residual disease after surgery and BCG treatment and distinguished recurrence risk based on tumour DNA findings.
Astellas terminated its phase 1 ASP5502 study in Sjögren’s syndrome as Novartis said the FDA granted breakthrough therapy designation to ianalumab. Novartis plans global regulatory submissions from early 2026 after positive phase III data.
Eli Lilly and Co. expanded its collaboration with Hong-Kong listed Insilico Medicine Inc. in a deal worth up to $2.75 billion. The move deepens Lilly's investment in artificial intelligence-driven drug discovery and could broaden its reach into next-generation metabolic therapies.
Diabetes and heart disease can impair sexual function by damaging blood vessels, nerves and circulation. Sexual dysfunction may also be an early warning sign of underlying vascular damage.
Trump’s April 2, 2026 proclamation imposes Section 232 tariffs of up to 100% on patented pharmaceutical imports and ingredients. Generic drugs and biosimilars are excluded.
A global analysis of early-onset gastric cancer found mortality declining 2.9% annually from 1990 to 2021, while disparities between high- and low-income regions widened. In 2021, the disease accounted for about 125,000 new cases, 78,000 deaths, and 3.86 million DALYs worldwide.
NRx said the FDA issued a positive review letter on its preservative-free ketamine ANDA, requesting only minor administrative changes. The company also received FDA guidance outlining a path to an NDA for NRX-100 using clinical trial data and real-world evidence.
AI is reshaping pharma work by adding roles in drug discovery, commercial analytics and in-house AI teams rather than driving major job losses. Companies are also moving toward always-on intelligence as faster market shifts expose the limits of siloed, episodic insight models.
Ascentage Pharma said six clinical abstracts were selected for ASCO 2026 and four preclinical studies will be presented at AACR 2026. The presentations feature olverembatinib and other pipeline candidates.
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
The UK has begun a 4,000-volunteer H5N1 bird flu vaccine trial using mRNA technology. The study will assess safety and immune response, with CEPI providing £40m in funding.
Novartis reported 2025 sales of $54.5 billion, up 8%, while earnings per share rose 15% to $8.98. Amarin reported fiscal 2025 revenue of $213.6 million, down 6.5%, and narrowed its net loss per share to $0.09 from $0.20.
